



# Regent Pacific Group Limited

(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

30 March 2015

## ANNOUNCEMENT


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

### **PLETHORA SOLUTIONS HOLDINGS PLC ABBREVIATED AUDITED RESULTS FOR YEAR ENDED 31 DECEMBER 2014**

This announcement is made by Regent Pacific Group Limited (the “**Company**”) in compliance with the disclosure requirements under Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The Board of the Company refers to the RNS announcement made by Plethora Solutions Holdings plc (“**Plethora**”), an associate of the Company since 1 January 2014 under applicable accounting standards, on the Alternative Investment Market of the London Stock Exchange on 30 March 2015 (after market close in Hong Kong) in respect of its abbreviated audited results for the year ended 31 December 2014 (the “**UK Announcement**”). A full copy of its Annual Report for the financial year ended 31 December 2014 is available through Plethora’s web site [www.plethorasolutions.co.uk](http://www.plethorasolutions.co.uk).

In the UK Announcement, Plethora reported the following abbreviated audited results for the financial year ended 31 December 2014:





- Revenues of £3.9 million (approximately US\$5.8 million or HK\$45.2 million ) (2013: nil)
- Loss before tax and pre-exceptional costs\* of £0.3 million (approximately US\$0.4 million or HK\$3.1 million)
- Loss from continuing operations for the year (post exceptional costs\*) of £15.7 million (approximately US\$23.3 million or HK\$181.7 million) (2013: loss of £8.8 million (approximately US\$13.1 million or HK\$102.2 million))
- Loss per share 3.2 pence (approximately US cents 4.8 or HK cents 37.4) (2013: loss of 2.6 pence (approximately US cents 3.9 or HK cents 30.4))
- Cash and cash equivalent of £5.1 million (approximately US\$7.6 million or HK\$59.3 million) (2013: £3.1 million (approximately US\$4.6 million or HK\$35.9 million))

\* exceptional costs relate to the acquisition of residual royalty rights by Plethora from external parties, including the original patent holder, such that Plethora owns the entire economic benefit of all future revenue streams generated from the 'out licensing' of PSD502™, a treatment for premature ejaculation, in the future on a global basis.

The UK Announcement further disclosed that Plethora is currently involved in discussions and negotiations with:

- (i) a global pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for certain countries in LATAM, Asia Pacific (including Australia) and South Africa. The parties have entered into non-binding heads of terms and have moved into discussions on the license agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales.
- (ii) a multinational pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for countries in the Middle East region. The parties have entered into non-binding heads of terms and have moved into discussions on the license agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales.

Plethora reported that negotiations continue for the licensing out of PSD502™ with both these pharmaceutical companies and with other strategic commercial marketing partners on normal commercial terms. However, Plethora noted that it is not possible to determine with accuracy the timing of completion of such agreements and no assurance can be given that negotiations will lead to a binding licensing agreement(s) as described in (i) and/or (ii) above or at all. Plethora publicly stated that it hopes to be in a position to make further announcements during the course of 2015 relating to its out licensing activities.



Note: Unless otherwise specified herein, (i) amounts denominated in £ have been translated, for the purpose of illustration only, into US\$ using the exchange rate of £1.00 = US\$1.4865; and (ii) amounts denominated in US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On behalf of the Board of  
**Regent Pacific Group Limited**

Jamie Gibson  
*Executive Director*

**Directors of the Company:**

James Mellon (*Co-Chairman*)<sup>\*</sup>  
Stephen Dattels (*Co-Chairman*)<sup>\*</sup>  
Jamie Gibson (*Chief Executive Officer*)  
David Comba<sup>#</sup>  
Julie Oates<sup>#</sup>  
Mark Searle<sup>#</sup>  
Jayne Sutcliffe<sup>\*</sup>

<sup>\*</sup> *Non-Executive Directors*

<sup>#</sup> *Independent Non-Executive Directors*

Hong Kong, 30 March 2015